Who is sponsoring NCT00766831?

NCT00766831 is sponsored by Janssen Korea, Ltd., Korea.

What condition does NCT00766831 study?

NCT00766831 studies Cancer Pain.

What is the status of NCT00766831?

NCT00766831 is currently COMPLETED.

Last reviewed 2013-09-13 · How we verify

Hydromorphone OROS in Korean Cancer Patients: Evaluation of Its Clinical Usefulness in Improvement of Sleep Disturbance

NCT00766831 Phase 4 COMPLETED Results posted

The purpose of this is study to evaluate improvement of sleep disorder caused by cancer pain after the administration of Hydromorphone Oral Osmotic System (OROS) in Korean participants with cancer.

Details

Lead sponsor	Janssen Korea, Ltd., Korea
Phase	Phase 4
Status	COMPLETED
Enrolment	190
Start date	2008-10
Completion	2010-06

Conditions

Cancer Pain

Interventions

Hydromorphone

Primary outcomes

Percentage of Treatment Response in Sleep Disturbance Caused by Cancer Pain — Day 15 or Early withdrawal
Percentage of treatment response in sleep disturbance caused by cancer pain was reported. Treatment response in sleep disturbance was measured by Numeric Rating Scale (NRS) ranging from 0=no disturbance to 10=extreme disturbance.